| Literature DB >> 24468054 |
Kazufumi Nakashima, Kazuyoshi Shigehara1, Shohei Kawaguchi, Akira Wakatsuki, Yoshitomo Kobori, Kazuyoshi Nakashima, Yasunori Ishii, Masayoshi Shimamura, Toshiyuki Sasagawa, Yasuhide Kitagawa, Atsushi Mizokami, Mikio Namiki.
Abstract
BACKGROUND: Oropharyngeal squamous cell carcinoma (OSCC) has shown a gradual increase in male predominance due to the increasing incidence of human papillomavirus (HPV)-associated OSCC. However, the mode of HPV transmission to the oral cavity is poorly understood, and little is known about the epidemiology of oral HPV infection in men. The prevalence rates of HPV, Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma spp., and Ureaplasma spp. were compared in the oropharynx (oral cavity) and urine of male Japanese patients attending a sexually transmitted disease clinic.Entities:
Mesh:
Year: 2014 PMID: 24468054 PMCID: PMC3907364 DOI: 10.1186/1471-2334-14-43
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Patient backgrounds ( = 213)
| Mean age (range) | 34.3 (16 – 70) |
| Number of patients with urethritis | 91 (43%) |
| Gonococcal | 17 |
| Chlamydial | 31 |
| Gonococcal and chlamydial | 2 |
| Non-gonococcal and non-chlamydial | 41 |
| Number of patients non-urethritis | 122 (57%) |
| | 2 |
| Asymptomatic | 1 |
| Asymptomatic (for STD check) | 119 |
STD, sexually transmitted disease.
Results of PCR analysis of oral samples and urine samples by liquid-based cytology
| | |||
|---|---|---|---|
| Number of adequate samples (%) | 213 (100%) | 208 (97.7%) | |
| HPV detection rate (%) | 40 (18.8%) | 46 (22.1%) | 0.331 |
| High-risk HPV detection rate (%) | 30 (14.1%) | 32 (15.4%) | 0.575 |
| Low-risk HPV detection rate (%) | 12 (5.6%) | 19 (9.1%) | 0.276 |
| Frequency of single-type HPV infection (%) | 30 (75.0%) | 24 (52.2%) | 0.029 |
| 36 (15.6%) | 19 (9.1%) | 0.018 | |
| 9 (4.2%) | 33 (15.9%) | < 0.001 | |
| 11 (5.2%) | 16 (7.7%) | 0.290 | |
| 22 (10.3%) | 13 (6.3%) | 0.130 | |
| 34 (16.0%) | 40 (19.2%) | 0.378 |
PCR, polymerase chain reaction; HPV, human papillomavirus.
Type-specific prevalence rates of HPV in oral and urine samples
| | | |
| 16 | 17 (42.5) | 19 (41.3) |
| 18 | 7 (17.5) | 11 (23.9) |
| 33 | 5 (12.5) | 6 (13.0) |
| 39 | - | 1 (2.2) |
| 52 | 1 (2.5) | 3 (6.5) |
| 53 | - | 2 (4.3) |
| 58 | 1 (2.5) | 3 (6.5) |
| 59 | 1 (2.5) | 2 (4.3) |
| 66 | - | 1 (2.2) |
| | | |
| 6 | 8 (20.0) | 11 (23.9) |
| 11 | 5 (12.5) | 10 (21.7) |
| | | |
| 1 (2.5) | 2 (4.3) |
HPV, human papillomavirus.
Details of HPV types in cases in which HPV was detected from both oral and urine samples
| Case 1 | 16 | 16, 52 |
| Case 2 | 16 | 16, 18 |
| Case 3 | 16, 33 | 11, 16, 33 |
| Case 4 | 16, 33 | 33 |
| Case 5 | 16, 33 | 16, 33 |
| Case 6 | 18 | 18 |
| Case 7 | 18 | 18 |
| Case 8 | 6 | 18 |
| Case 9 | 6, 16 | 6 |
| Case 10 | 16 | 16, 53 |
| Case 11 | 16 | 6, 16 |
| Case 12 | 6 | 6 |
| Case 13 | 16 | 16 |
| Case 14 | 16 | 16 |
| Case 15 | 16 | 16 |
| Case 16 | 6, 11 | 11 |
| Case 17 | 18 | 11 |
| Case 18 | 18 | 18 |
HPV was detected in both oral and urine samples from 16 cases.
HPV, human papillomavirus.
Univariate and multivariate analyses of risk factors for detection of any HPV infection in oral samples
| | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | |
| < 35 | 115 | 23 | 92 | 1.0 (referent) | | | 1.0 (referent) | | |
| ≥ 35 | 98 | 17 | 81 | 0.65 | 0.12–1.70 | 0.647 | 0.71 | 0.32–1.58 | 0.402 |
| | | | | | | | | | |
| negative | 167 | 22 | 145 | 1.0 (referent) | | | 1.0 (referent) | | |
| positive | 46 | 18 | 28 | 4.24 | 2.02–8.91 | <0.001 | 3.39 | 1.49–7.71 | 0.004 |
| | | | | | | | | | |
| negative | 122 | 28 | 94 | 1.0 (referent) | | | 1.0 (referent) | | |
| positive | 91 | 12 | 79 | 0.51 | 0.24–1.07 | 0.0711 | 0.78 | 0.32–1.81 | 0.532 |
| | | | | | | | | | |
| 177 | 38 | 139 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 36 | 2 | 34 | 0.22 | 0.05–0.94 | 0.016 | 0.096 | 0.01–0.77 | 0.027 |
| 204 | 39 | 165 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 9 | 1 | 8 | 0.53 | 0.06–4.35 | 0.470 | 0.39 | 0.03–4.69 | 0.460 |
| 202 | 39 | 163 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 11 | 1 | 10 | 0.42 | 0.05–3.36 | 0.353 | 0.28 | 0.02–3.10 | 0.296 |
| 191 | 35 | 156 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 22 | 5 | 17 | 1.31 | 0.45–3.79 | 0.398 | 0.68 | 0.10–4.50 | 0.692 |
| 179 | 33 | 146 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 34 | 7 | 27 | 1.15 | 0.46–2.86 | 0.464 | 0.52 | 0.09–3.16 | 0.478 |
| 126 | 26 | 100 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 87 | 14 | 73 | 0.74 | 0.36–1.51 | 0.405 | 3.84 | 0.59–27.92 | 0.184 |
| | | | | | | | | | |
| 194 | 38 | 156 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 19 | 2 | 17 | 0.48 | 0.11–2.18 | 0.267 | 0.56 | 0.04–7.62 | 0.663 |
| 180 | 38 | 142 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 33 | 2 | 31 | 0.24 | 0.06–1.05 | 0.051 | 0.21 | 0.02–2.10 | 0.186 |
| 197 | 39 | 158 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 16 | 1 | 15 | 0.27 | 0.04–2.11 | 0.158 | 0.64 | 0.05–8.77 | 0.737 |
| 200 | 38 | 162 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 13 | 2 | 11 | 0.78 | 0.17–3.64 | 0.545 | 0.42 | 0.06–2.96 | 0.380 |
| 173 | 31 | 142 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 40 | 9 | 31 | 1.33 | 0.58–3.07 | 0.320 | 1.29 | 0.12–10.60 | 0.814 |
| 116 | 26 | 90 | 1.0 (referent) | | | 1.0 (referent) | | | |
| positive | 97 | 14 | 83 | 0.58 | 029–1.19 | 0.140 | 0.94 | 0.09–9.43 | 0.958 |
HPV, human papillomavirus.